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An increase in the incidence of rare but hard-to-treat invasive fungal pathogens as well as resistance 24 
to the currently available antifungal drugs calls for new broad-spectrum antifungals with a novel 25 
mechanism of action. Here, we report the identification and characterization of two novel zinc-26 
attenuating compounds ZAC307 and ZAC989, which exhibit broad-spectrum in vitro antifungal 27 
activity and in vivo efficacy in a fungal kidney burden candidiasis model.  28 
The compounds were identified serendipitously as part of a drug discovery process aimed at finding 29 
novel inhibitors of the fungal plasma membrane proton ATPase, Pma1. Based on their structure, we 30 
hypothesized that they might act as zinc chelators. Indeed, both fluorescence-based affinity 31 
determination and potentiometric assays revealed these compounds, subsequently termed zinc 32 
attenuating compounds (ZACs), to have strong affinity for zinc, and their growth inhibitory effects 33 
on Candida albicans and Aspergillus fumigatus could be inactivated by the addition of exogenous 34 
zinc to fungal growth media. We determined the ZACs to be fungistatic, with a low propensity for 35 
resistance development. Gene expression analysis suggested that the ZACs interfere negatively with 36 
the expression of genes encoding the major components of the A. fumigatus zinc uptake system, 37 
thus supporting perturbance of zinc homeostasis as the likely mode of action. Taken together, with 38 
demonstrated in vitro and in vivo antifungal activity, low propensity for resistance development, 39 
and a novel mode of action, the ZACs represent a promising new class of antifungal compounds, 40 














Introduction   46 
The success of pathogenic microorganisms hinges upon their ability to sequester essential nutrients 47 
from their host during infection. Through a process known as nutritional immunity, the host 48 
immune system sequesters metals that are necessary for microbial growth, resulting in an extremely 49 
nutrient-limited host environment (1). For example, vertebrates express a number of iron-binding 50 
molecules, e.g., the transferrin family, that ensure extremely low concentrations of free iron in the 51 
body (2). Additionally, neutrophils and other myeloid and non-myeloid cells synthesize large 52 




-chelating protein calprotectin during infection, and the 53 
contribution of calprotectin to the innate immune response against yeast and filamentous fungal 54 
pathogens is well documented (3–5). 55 
For fungal pathogens to grow and establish infection inside their host, they must be able to obtain 56 
iron, zinc, and other essential metals from the harsh environment imposed by nutritional immunity 57 
(6). Consequently, successful pathogens have evolved elegant mechanisms to sequester essential 58 
metals from their hosts during infection. The mechanisms for iron sequestration are best described, 59 
and include the expression of high affinity iron transporters, iron-chelating siderophores and iron-60 
binding proteins (1, 7, 8). Although iron acquisition is recognized as a virulence factor for many 61 
fungal pathogens (7), research in recent years has highlighted the important contribution that zinc 62 
sequestration makes to fungal pathogenesis and virulence (4, 9). Indeed, fungal acquisition of zinc 63 
has been clearly demonstrated to be essential for fungal growth and pathogenicity and zinc-64 
depleting conditions are known to reduce fungal growth in vitro (3, 10, 11). 65 
 66 




 superoxide dismutases 67 
(SODs), alcohol dehydrogenase and ribosomal proteins (12). SODs are key enzymes in fungal 68 
virulence and are necessary for the detoxification of reactive oxygen species generated by host cells 69 
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during fungal infection (13). In A. fumigatus, zinc uptake is regulated by the transcriptional 70 
regulator ZafA, and deletion of zafA has been shown to not only impair germination and overall 71 
growth capacity of A. fumigatus in zinc-limiting media, but it also completely abrogates A. 72 
fumigatus virulence in a murine model of invasive aspergillosis (11). Thus, the control of access to 73 
zinc is one of the central battlefields on which the outcome of an infection is decided. In further 74 
support of this notion, calprotectin comprises ~40% of total protein content in the neutrophil 75 
cytoplasm during infection, and its antifungal effect can be reversed in vitro by micromolar 76 
quantities of zinc (3, 4, 9). Because of the great need for fungal zinc uptake during infection, it has 77 
been hypothesized that both chelation therapy and the modulation of zinc homeostasis and zinc 78 
acquisition are promising antifungal strategies (14–18). 79 
 80 
We have previously reported the identification of novel antifungal compounds targeting the fungal 81 
plasma membrane H
+
-ATPase (19, 20). In the further optimization process a number of compounds 82 
were synthesized, and we found two of these compounds, ZAC307 and ZAC989, to be very potent 83 
inhibitors of Candida albicans growth, despite the fact that they lacked H
+
-ATPase inhibitory 84 
activity. Due to their characteristic arrangement of an aromatic structure with nitrogen bound in 85 
close proximity to a hydroxyl group, we speculated that ZAC307 and ZAC989 could act as metal 86 
chelators. Thus, the goals of this study were: i) to investigate the chelating properties of these 87 
compounds; ii) to characterize the spectrum of antifungal activity of these compounds in vitro; iii) 88 
to ascertain whether the compounds were fungistatic or fungicidal, and the propensity of C. 89 
albicans to develop resistance against these compounds; iv) to investigate whether the antifungal 90 
activity was caused by extracellular zinc sequestration or if the compounds were taken up by 91 
Candida albicans cells; v) to assess whether or not these compounds influenced the expression level 92 
of genes encoding zinc transporters required for zinc uptake from zinc-limiting media and that of 93 
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other genes regulated by ZafA, which is the master regulator of zinc homeostasis in Aspergillus 94 
fumigatus, and vi) to test and evaluate the effects of these compounds against mammalian cells and 95 
their antifungal efficacy in vivo in a murine model of candidiasis. 96 
 97 
Results 98 
ZAC307 and ZAC989 have high binding affinity for zinc and copper, but not for magnesium and 99 
calcium  100 
ZAC307, ZAC989, ZAC623 (collectively referred to as ZACs) and the reference compounds EDTA 101 
and TPEN (Fig. 1) were evaluated for their zinc binding properties. ZAC307 and ZAC989 have 102 
dissociation constants (KD) in the low nanomolar range (KD = 13 – 71 nM), as determined by a 103 
fluorescence-based competition assay (Table 1). ZAC623 exhibited poor affinity for zinc, with a 104 
dissociation constant > 6 µM. Dissociation constants for EDTA and TPEN could not be determined 105 
with this assay as their dissociation constants were below the measurable range, but both have 106 
previously been reported to be very potent zinc chelators (21). 107 
The Zn
2+
-binding properties of ZAC307 and ZAC989 were further evaluated using a potentiometric 108 
assay, where pH is measured as a function of base (NaOH) added to the compound, either in the 109 
absence or presence of metal. Since potentiometric methods require millimolar concentrations, and 110 
ZAC307 and ZAC989 displayed poor solubility in water at such high concentrations, the 111 
measurements were performed in a mixture of DMSO/water (70:30 v/v), as described previously 112 
(22). To determine the deprotonation constant, a solution of 1 mM ZAC307 or ZAC989 was titrated 113 
with 0.3 M NaOH at constant ionic strength (Fig. 2A and 2B). In a second run, the same titration 114 
was performed in the presence of 0.5 equivalents of Zn
2+
 for ZAC307 and ZAC989. A shift in the 115 
pH curve in the presence of the metal (Fig 2A: ZAC307, 0.5eq Zn
2+
) as compared to the absence of 116 
the metal (Fig 2A: ZAC307) indicates binding of the Zn
2+
 to the compound. The measured pH data 117 
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were analyzed with the Hyperquad program suite, taking into account all relevant equilibrium 118 
constants, including also the constants for metal hydroxylation. The analysis provides the pKa 119 
values and metal complex stability constants, as well as a speciation calculation, indicating how 120 
many ZAC molecules are involved in coordinating the Zn
2+
 ion at different pH values. Refinement 121 
of the measured pH data for ZAC307 provided a pKa value of 6.84, and formation constants log β1, 122 
log β2, and log β3 of 7.47, 13.27, and 18.14, corresponding to the formation of a 1:1, 2:1, and 3:1 123 
ligand-Zn(II) complex, respectively. The corresponding species distribution diagram is displayed in 124 
Fig. 2C and this shows that, at neutral pH in a DMSO/water solvent mixture, the ligand-zinc 125 
stoichiometry is a mixture of 1:1, 2:1 and 3:1 binding, with 2:1 and 3:1 being the dominant 126 
stoichiometries. Similar potentiometric experiments were carried out with CaCl2 and MgCl2 in 127 




 binding to ZAC307 is negligible (Fig. 128 
2A). Potentiometric titration of ZAC307 with CuSO4 was not possible due to precipitation of the 129 
resulting complex suggesting that ZAC307 also binds copper. Refinement of the measured pH data 130 
for ZAC989 provided a pKa value of 7.70, and in the presence of zinc we measured formation 131 
constants log β1, log β2, and log β3 of 7.35, 14.30, and 19.71, corresponding to the formation of a 132 
1:1, 2:1, and 3:1 ligand-Zn(II) complex, respectively (Fig. 2D). Potentiometric experiments were 133 
also carried out with ZAC989 and CuSO4, CaCl2 and MgCl2, and the data indicated that ZAC989 134 
chelates copper, whereas binding of calcium and magnesium is negligible. ZAC989 bound copper 135 
with the formation constants log β1, log β2, and log β3 of 7.83, 13.37, and 20.62, respectively. The 136 
most dominant ZAC989-copper stoichiometry was a 3:1 stoichiometry (Fig. 2E). 137 
 138 
ZACs are potent broad-spectrum fungistatic yeast inhibitors that work intracellularly and display 139 
low potential for resistance development 140 
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ZAC307 and ZAC989 exhibit antifungal activity, and display potent growth inhibition in the low 141 
µg/mL range (0.2 – 0.9 µg/mL) against a number of pathogenic Candida species, including a 142 
Candida glabrata strain with increased efflux pump activity (Table 2). The minimum inhibitory 143 
concentration (MIC) was defined as the lowest compound concentration that resulted in at least 144 
50% growth inhibition for yeasts, which corresponded to a prominent decrease in visible growth. 145 
For molds the MIC was defined as the lowest concentration of the compound that resulted in no 146 
visible growth. In Candida albicans this value was 0.6 µg/mL for ZAC989 and 0.4 µg/mL for 147 
ZAC989. ZAC623 did not display growth inhibitory activity against C. albicans (Fig. 3A). The 148 
known potent metal chelators EDTA and TPEN both exhibited a MIC of ~0.05 µg/mL, but TPEN 149 
led to a more complete growth inhibition as compared to EDTA (Fig. 3B). The antifungal effects of 150 
ZAC989 and ZAC307 were reversed by exogenous addition of zinc or copper to the growth 151 
medium in the presence of either ZAC989 or ZAC307 (Fig. 3C and 3D). Zinc ions were most 152 
effective in reversing the growth inhibitory effects of the ZACs, with restoration of fungal growth 153 
observed in the presence of 1 µM Zn
2+
. Addition of iron (Fe
2+
) had a modest effect on the 154 
antifungal activity of ZAC989 and ZAC307, with a fungal growth rate of approximately 50% in the 155 
presence of 100 µM Fe
2+
 as compared to control cells. In accordance with the results obtained from 156 
potentiometric titration, the addition of magnesium or calcium had no effect on the antifungal 157 
activity of the ZACs (Fig. 3C and 3D).  158 
Time-kill investigations revealed that the ZACs exhibited fungistatic activity against C. albicans in 159 
contrast to amphotericin B (AMB), which exhibits fungicidal activity after 3 h of exposure (Fig. 160 
4A). Both EDTA and TPEN exhibited a fungistatic effect within the first 24 h of exposure. Fungal 161 
growth recovery was evaluated after longer exposure times of C. albicans cells to the ZACs. This 162 
revealed that the fungal cells were able to resume growth when moved to fresh growth media in the 163 
absence of ZACs (Fig. 4B). Fungal cells exposed to TPEN at concentrations above 2 µg/mL 164 
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showed poor recovery and this may be explained by the strong chelating properties of TPEN that 165 
enable it to extract zinc from essential enzymes leading to fungal cell death after prolonged 166 
exposure (Fig. 4C). 167 
In order to gain an understanding of the potential of ZACs to permeabilize into fungal cells, we 168 
monitored the intracellular zinc levels of C. albicans cells that were exposed to TPEN, EDTA or 169 
ZACs using the cell-permeable fluorescent probe zinbo-5. The affinity constant of this probe for 170 
zinc is 2.2 nM (23), which is weaker than that of most zinc-binding proteins, and thus it only reports 171 
the free or weakly bound zinc ions. The probe localizes to the internal membrane system including 172 
the ER in C. albicans (L. Kjellerup, A. L. Winther, D. Wilson, and A. T. Fuglsang, submitted for 173 
publication). A decreased zinbo-5-fluorescent signal in the presence of fungal cells, compound and 174 
zinc would indicate that intracellular zinbo-5 is competing with the added compound for zinc ions. 175 
ZAC307 and ZAC989 were evaluated at a concentration of 25 µM, equivalent to 7 µg/mL and 9 176 
µg/mL respectively. ZAC989 induced a time-dependent decrease in zinbo-5 fluorescence, similarly 177 
to 1.3 µg/mL TPEN (Fig. 4D). ZAC307 decreased the zinbo-5 fluorescence after only 1 h of 178 
incubation, and this decrease was greater than that observed for ZAC989 (Fig. 4D), despite 179 
ZAC307 having a 5-fold lower affinity for zinc than ZAC989. These data suggested that ZAC307, 180 
ZAC989 and TPEN were cell-permeable and bound intracellular zinc. In agreement with this, the 181 
extracellular chelator EDTA did not reduce the zinbo-5 fluorescence under the same conditions.   182 
We investigated the propensity for resistance development to ZAC307 and ZAC989 by repeated 183 
exposure of C. albicans to ZACs in SDwoz media over a 36-day period. We observed no change in 184 
the MIC for the ZACs after repeated ZAC-exposure. In contrast, cells repeatedly exposed to 185 
fluconazole exhibited a significant increase in the MIC to fluconazole after 22 passages (Fig. 4E). 186 
Based on these results, it appeared that ZAC resistance was not easily induced in C. albicans. 187 
 188 
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ZACs efficiently inhibit the growth capacity of Aspergillus fumigatus under zinc-limiting 189 
conditions and their inhibitory effects are inactivated by zinc 190 
In addition to potent antifungal effects on the five Candida species tested, ZAC307 and ZAC989 191 
also potently inhibited the mold Aspergillus fumigatus and other Aspergillus species, as well a 192 
number of rare but very hard-to-treat members of the Mucorales order including Rhizopus oryzae, 193 
Rhizopus microspores, and Mucor indicus. The ZACs inhibited these molds and mucorales isolates 194 
in a range from 0.4 µg/mL to 5.4 µg/mL (Table 3). To assess the capacity of the ZACs to inhibit A. 195 
fumigatus growth in the presence of zinc, 1 mL aliquots of the sRPMI zinc-limiting medium, or this 196 
medium supplemented with 2, 5 or 50 μM zinc were inoculated with 10
5
 conidia of a wild-type A. 197 
fumigatus strain (AF14), dispensed in 24-well culture plates and incubated in the presence of either 198 
ZAC307 or ZAC989 at a final concentration 21 μg/mL and 27 µg/mL (equivalent to 75 µM), 199 
respectively (Fig. 5A). Graphical representation and quantification of the fungal growth in 24-well 200 
culture plates in the presence of ZACs (Fig. 5A) revealed that the growth capacity of a wild-type A. 201 
fumigatus strain was reduced under zinc-limiting conditions but increased gradually when the 202 
growth medium was supplemented with increasing amounts of zinc, until fungal growth was fully 203 
restored when cultured in media supplemented with 50 μM Zn (i.e. under zinc replete conditions). 204 
Hence, the inhibitory effects of the ZACs against A. fumigatus were completely counteracted by 205 
simultaneous addition of zinc, similarly to our observations in C. albicans (Fig. 3C and 3D). 206 
 207 
The zinc transporter ZrfC plays an important role in regulating fungal sensitivity to the ZACs  208 
To ascertain whether ZAC307 and ZAC989 interfered with zinc uptake from the sRPMI zinc-209 
limiting medium, we analyzed their effects on the growth capacity of the mutant strains AF48 210 
(ΔzrfAΔzrfB), AF721 (ΔzrfAΔzrfBΔzrfC), AF731 (ΔzrfAΔzrfBΔzrfC [zrfC]), which is an AF721 211 
derivative strain that carries the zrfC gene reintroduced at the pyrG locus as described previously 212 
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(24), and AF54 (ΔzrfC) (Fig. 5B to Fig. 5E). The overall effect of the ZACs on the growth capacity 213 
of the AF48 strain was similar to that of the wild-type strain AF14 (compare Fig. 5A and 5B). In the 214 
absence of ZACs both strains exhibited a reduced the growth capacity from 100% to 70%, when 215 
cultured in media supplemented with 50 µM as compared to media supplemented with 2 µM zinc. 216 
This corresponded to a 1.4-fold reduction in growth capacity. However, in the presence of 2 µM 217 
zinc plus 75 µM ZAC307 the growth capacity of AF14 and AF48 was reduced respectively by 2.9 218 
and 3.9-fold as compared to that in the presence of 50 µM zinc. Similarly, 2 µM zinc plus 75 µM 219 
ZAC989 reduced the growth capacity of AF14 and AF48 by 3.9 and 4.5-fold, respectively. The 220 
AF721 strain did not grow under zinc-limiting conditions, and hence the effect of these compounds 221 
could not be tested on this strain (Fig. 5C). The reintroduction of zrfC in a strain with a 222 
ΔzrfAΔzrfBΔzrfC genetic background restored the fungal growth capacity in the presence of the 223 
ZACs (Fig. 5D) at the same level as that of the wild-type and AF48 strains (Fig. 5A and 5B). 224 
Finally, in the presence of 2 µM zinc either with or without simultaneously exposure to ZAC307 or 225 
ZAC989 the growth capacity of the AF54 strain was reduced by an average of 24.6-fold as 226 
compared to its growth capacity in the presence of 50 µM zinc, (Fig. 5E), i.e. the ZACs were 227 
between 5 and 8-fold more efficient as inhibitors of the growth capacity of a ΔzrfC strain than of a 228 
wild-type or ΔzrfAΔzrfB strain, which suggested that the effect of ZACs could be counteracted to a 229 
certain extent by the function of ZrfC. 230 
 231 
ZAC307 and ZAC989 inhibit the transcription of genes regulated by ZafA under zinc-limiting 232 
conditions  233 
The major regulator of the A. fumigatus zinc homeostatic response under zinc-limiting conditions is 234 
the transcription factor ZafA (11), which is a zinc-responsive factor that senses the intracellular 235 
concentration of zinc in a similar way to its orthologue Zap1 in the yeast Saccharomyces cerevisiae 236 
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(25). Thus, when the cytoplasmic zinc content is high enough, ZafA becomes saturated with Zn
2+
 237 
ions and adopts a transcriptionally inactive conformation. In contrast, when the intracellular 238 
concentration drops below a certain threshold, ZafA begins to release Zn
2+
 ions and gradually 239 
adopts a transcriptionally active conformation, whereby it is able to induce the expression of zrfA 240 
and zrfB in acidic zinc-limiting media, and zrfC in alkaline zinc-limiting media (11, 24).  241 
We employed qRT-PCR to assess whether exposure to ZAC307, ZAC989, EDTA or TPEN 242 
influenced the expression of several ZafA target genes and other genes not regulated directly by 243 
ZafA (as controls) (Table 4). The set of genes investigated was selected based on a genome-wide 244 
transcription analysis of A. fumigatus grown under zinc-limiting conditions that had been performed 245 
previously in our laboratory (Calera, JA; unpublished data), using the primers listed in Table 5. All 246 
selected ZafA target genes were induced by ZafA under zinc-limiting conditions with the exception 247 
of the putative zinc storage vacuole transporter zrcA, which was repressed by ZafA under zinc-248 
limiting conditions (Calera JA; unpublished data). As expected, the relative expression levels of all 249 
ZafA target genes induced by ZafA under zinc-limiting conditions were dramatically reduced to 250 
almost undetectable levels upon the addition of Zn
2+
 (Fig. 6). In contrast, the expression level of the 251 
zrcA gene, which was repressed by ZafA, and most of the genes not regulated by ZafA increased 252 
under zinc-replete conditions to different extents, with the exception of actA, whose expression 253 
level remained similar to that observed before the zinc-shock. Interestingly, exposure to either 254 
ZAC307 or ZAC989 inhibited the expression of the ZafA target genes at similarly. We also 255 
observed reduced expression levels for most of the investigated genes that were not regulated by 256 
ZafA following ZAC307 exposure. In particular, the expression level of pmaA, which encodes the 257 
orthologue of the Pma1 H
+
-ATPase from S. cerevisiae, and that of the gdpA and tubB1 genes were 258 
reduced at levels similar to that of the ZafA target genes (Fig. 6). In contrast, treatment with 259 
ZAC989 did not have a noticeable effect on the expression levels of the genes not regulated by 260 
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ZafA, which remained similar to that observed under zinc-limiting conditions (Fig. 6). This finding 261 
suggested that although the overall outcome of the treatment with ZAC307 and ZAC989 on ZafA 262 
regulated genes was quite similar, the precise mode of action of ZAC307 on gene expression was 263 
different to that of ZAC989, which appeared to inhibit the ZafA regulated genes more specifically 264 
than ZAC307. 265 
Finally, we anticipated that chelation of extracellular zinc upon addition of a relatively high 266 
concentration of EDTA to the culture media for a short period of time (2 h) would result in a 267 
transient hyperactivation of ZafA and concomitant upregulation of the most direct ZafA target 268 
genes, including those encoding zinc transporters. We expected to observe the same effect with 269 
TPEN treatment, although in this case chelation of intracellular zinc should exacerbate the zinc 270 
starvation status of the fungal cells, leading to a more extended hyperactivation of ZafA and higher 271 
expression of the ZafA target genes compared to that attained with EDTA after the same incubation 272 
period. The expression profile for the ZafA regulated genes observed in EDTA- or TPEN-treated 273 
cultures reflected precisely what we predicted (Fig. 6). 274 
In summary, these results suggested that the antifungal effects of ZAC307 and ZAC989 were most 275 
likely mediated through a mechanism that ultimately results in the inhibition of the transcriptional 276 
activation activity of ZafA. 277 
 278 
Cytotoxicity and off-target activity studies 279 
ZAC307, ZAC989, EDTA and TPEN were evaluated for mammalian cytotoxicity in a standard 280 
hepatocyte cell proliferation assay, where the mammalian HepG2 cell line was exposed to the 281 
compounds for either 24 h or 72 h. After a 24 h exposure period to ZAC307 or ZAC989, the EC50 282 
was >28 µg/mL, while after 72 h of exposure the EC50 was 13.2 µg/mL and 6.9 µg/mL, respectively 283 
(Table 6). With antifungal activity against yeast and the mucorales isolates in the 0.2 - 1.7 µg/mL 284 
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range, the compounds exhibited a reasonable selectivity index towards mammalian cells. However, 285 
the selectivity index between the Aspergillus species and mammalian cells was limited. The non-286 
permeable chelator EDTA did not affect the proliferation of HepG2 cells, while the potent zinc 287 
chelator TPEN had an EC50 of 1.6 µg/mL after 24 h of exposure. 288 
 289 
ZACs exhibit in vivo efficacy in a murine fungal kidney burden candidiasis model 290 
ZAC989 and ZAC307 were investigated for in vivo efficacy in a fungal kidney burden model (Fig. 291 
7, Table 7). In this model, BALB/c mice were infected intraperitoneally (IP) on day 0. Initially, 292 
administration of ZACs included a pre-treatment 24 h prior (day –1) to infection (day 0) by IP 293 
route. The mice were then treated with either ZAC for 4 days (day –1 to day 2) to maximize the 294 
likelihood of observing in vivo efficacy. The endpoint was mean log colony forming unit (CFU) in 295 
the kidneys of treated animals compared to untreated animals. Fluconazole was chosen as a 296 
comparator compound and dosed PO, and treatment with fluconazole resulted in a significant 297 
reduction in kidney burden of 2.78 log CFU/kidney (Fig. 7). The in vivo studies also revealed that 298 
IP dosing of ZAC989 at 60 mg/kg resulted in a statistically significant reduction of 1.71 log 299 
CFU/kidney, while ZAC307 administration at 60 mg/kg led to a significant reduction of 1.06 log 300 
CFU/kidney. ZAC307 yielded equal in vivo efficacy with or without pre-treatment (Fig. 7, Table 7). 301 
We observed no adverse effects following dosing of 60 mg/kg of ZAC307, but for ZAC989, we 302 
observed lethargy lasting for 5-15 minutes after dosing. 303 
  304 
Discussion  305 
During this study, we identified a new series of zinc attenuating compounds with broad-spectrum 306 
antifungal activity in vitro and in vivo activity in a candidiasis fungal kidney burden model. The 307 
compounds ZAC307 and ZAC989 possess a characteristic arrangement of an aromatic structure 308 
 on M








with nitrogen bound in close proximity to a hydroxyl group. This structural arrangement led us to 309 
speculate whether ZAC307 and ZAC989 were metal chelators. To address this hypothesis, we 310 
synthesized ZAC623 as a control compound where the hydroxyl-group is replaced with an amino-311 
group, and as expected this compound lacked metal-chelating and antifungal properties (Fig. 1, 312 
Table 1 and Fig. 3A). The metal chelating compounds EDTA and TPEN have previously been 313 
described as antifungal compounds (16, 17, 26), thus they were selected as comparators in this 314 
study.  315 
Our findings indicate that ZAC307 and ZAC989 chelate both zinc and copper with zinc ions being 316 
most effective in reversing the growth inhibitory effects of the ZACs (Figure 3C and 3D). The 317 
ZACs has lower affinity for iron and negligible affinity for magnesium and calcium. The ZACs are 318 
less potent zinc chelators than the known zinc, copper and iron chelators TPEN and EDTA, but they 319 
inhibit fungal growth more effectively than EDTA (Fig. 3A and 3B). The inhibitory effects of the 320 
ZACs can be inactivated by the addition of excess zinc in both Candida albicans and Aspergillus 321 
fumigatus, which indicate that these compounds interfere either directly or indirectly with fungal 322 
zinc homeostasis.  323 
The first challenge that any microorganism faces in the homeostatic response to zinc deficiency is 324 
to obtain zinc from the surrounding environment. The major components of the zinc uptake system 325 
in A. fumigatus that facilitates zinc uptake from zinc-limiting media are the ZIP plasma membrane 326 
transporters ZrfA, ZrfB and ZrfC. The ZrfA and ZrfB transporters operate mainly under acidic zinc-327 
limiting conditions (27), although they also contribute to zinc uptake from alkaline zinc-limiting 328 
media along with ZrfC (3), which is expressed exclusively in alkaline media (24). Therefore, we 329 
reasoned that if the ZACs inhibited the intake of zinc mediated by these transporters, the growth 330 
capacity of a wild-type strain in the presence of ZACs should be reduced to the same level as that of 331 
fungal mutant strains lacking either the acidic (ZrfA and ZrfB) and/or the alkaline (ZrfC) zinc 332 
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transporter. The investigation of the growth capacity of a ∆zrfC mutant in the presence of the ZACs 333 
suggested that ZrfC plays an important role in overcoming ZAC inhibition, since deletion of zrfC 334 
increased the sensitivity of A. fumigatus to these compounds (AF14 vs. AF54, Fig. 5A and 5E). 335 
Hence, it could be possible that the actual effect of ZACs on the ∆zrfA∆zrfB strain was masked to 336 
some extent by the ZrfC function. As expected, the AF721 strain lacking zrfC did not grow under 337 
zinc-limiting conditions, and effect of these compounds could therefore not be tested on this strain 338 
(Fig. 5C). However, we observed that ZAC989 noticeably inhibited the growth capacity of AF721 339 
in the presence of 50 μM zinc. Thus, it is plausible that ZAC989 interfered with a zinc homeostatic 340 
process other than zinc uptake. Furthermore, the higher growth capacity of the ΔzrfC strain in the 341 
absence of ZACs compared to that of the wild-type, AF48 or AF731 strain, suggested that the lack 342 
of zrfC in AF54 may have been compensated for by the overexpression of zrfA and zrfB, as reported 343 
previously (3). On the other hand, the stronger growth inhibition of the growth capacity of the AF54 344 
strain in the presence of ZAC307 and ZAC989 compared to that of the wild-type, AF48 or AF731 345 
strain suggested that the expression levels of the zrfA and zrfB genes in AF54 were insufficient to 346 
counteract the effects of ZAC307 and ZAC989. Taken together, these results suggest that both 347 
ZAC307 and ZAC989 interfered negatively with the expression of the genes encoding zinc 348 
transporters rather than with their zinc uptake function. Indeed, gene expression analysis by RT-349 
qPCR suggested that the antifungal effects of ZAC307 and ZAC989 were mediated through a 350 
mechanism that ultimately results in inhibition of the transcriptional activation activity of ZafA. In 351 
addition, and since ZafA activity was inactivated by zinc under physiological conditions, the effects 352 
of ZAC307 and ZAC989 on the expression of ZafA-regulated genes could be exerted either 353 
directly, upon their binding to ZafA, or indirectly, by increasing the cytosolic concentration of Zn
2+
 354 
ions that would bind to and inactivate ZafA. Although direct binding of ZAC307 or ZAC989 to 355 
ZafA was an attractive possibility, we consider it more likely that the ZACs triggered a transient 356 
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rise in the cytosolic concentration of Zn
2+
 ions by favoring their releasing from cytosolic zinc 357 
ligands and/or zinc storage compartments (e.g. the vacuole). In the data presented in Fig. 4D we 358 
observed that the ZACs promote a decrease in the available zinc levels within the internal 359 
membrane system including the ER in C. albicans. This decrease can be explained either by a direct 360 
competition between zinbo-5 and ZACs within these compartments, or because the ZACs promote 361 
the release of zinc from the ER into the cytosol. The latter scenario could induce a higher 362 
concentration of zinc in the cytosol, and if the same situation occurs in A. fumigatus this could 363 
explain the decrease in transcription of the ZafA induced genes similarly to when zinc is added 364 
extracellularly. Moreover, since most intracellular eukaryotic zinc proteins bind zinc with a higher 365 
affinity than ZACs (Kd values for most zinc binding proteins are between 0.1 and 1.0 pM) (28), it is 366 
more likely that these compounds interfere with the regulation of zinc homeostasis by promoting 367 
the release of Zn
2+
 ions from intracellular storage compartments. Nevertheless, since acidification 368 
of cytoplasm can also promote zinc release from cytoplasmic zinc ligands (29), it could also be 369 
possible that the ZACs disturbed the activity of proteins involved in maintaining the pH 370 
homeostasis of the cytoplasm. In this regard, we observed that the expression level of pmaA was 371 
higher under zinc-replete than under zinc-limiting conditions. This finding suggests a putative 372 
interplay between the function of PmaA and the Zn
2+
 transport capacity of the fungal zinc 373 
transporters, provided that the expression level of the pmaA gene correlated with the H
+
-ATPase 374 
(PmaA) activity. It is known that the accumulation of zinc into the vacuole by CDF transporters 375 




 antiporter mechanism and it relies on the proton gradient 376 
generated by the V-ATPase (30). In contrast, and although it is not completely known how ZIP 377 
proteins transport zinc across the plasma membrane, it seems that it is not dependent on the proton 378 
gradient generated by the plasma membrane H
+
-ATPase but pH-dependent, such that intracellular 379 
acidification increases zinc transport whereas extracellular acidification decreases zinc transport 380 
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(31–33). In this regard, it is plausible that in the alkaline zinc-limiting conditions provided by the 381 
sRPMI medium, a low PmaA activity would increase intracellular acidification to favor zinc uptake 382 
by ZIP transporters located in the plasma membrane. In contrast, a high PmaA activity under zinc-383 
replete conditions would reduce intracellular acidification and increase extracellular acidification 384 
(e.g. to counteract the Zn
2+
-induced dissipation of the electrochemical gradient that is essential for 385 
fungal survival). The same reasoning could be applied to zinc transport by the ZrfF ZIP transporter 386 
located in the vacuolar membrane, such that the intravacuolar pH, which is kept lower than the 387 
cytosolic pH under normal conditions via V-ATPase activity, would favor the exit of Zn
2+
 ions into 388 
the cytosol. However, the unexpected finding that ZAC307 reduces pmaA expression suggested that 389 
it might interfere with the putative mechanism that links the regulation of zinc homeostasis with the 390 
function of PmaA. 391 
The ZACs display broad-spectrum fungistatic activity and exhibit a low propensity for acquired 392 
resistance development, compared to fluconazole. Additionally, they are superior antifungal agents 393 
than the non-permeable chelator EDTA, and our qRT-PCR data suggest that the ZACs affect fungal 394 
zinc homeostasis differently to the very potent chelator TPEN. Therefore, the ZACs act distinctly 395 
from either EDTA or TPEN, both of which have previously been investigated as antifungal agents. 396 
EDTA has been evaluated as a combination treatment together with amphotericin B lipid complex 397 
(ABLC) in an invasive pulmonary aspergillosis model in immunosuppressed rats. The combination 398 
of EDTA with ABLC led to improved survival times and a lower tissue burden of A. fumigatus than 399 
either agent alone (26). Furthermore, TPEN has been shown to significantly increase survival after 400 
7 days compared to vehicle treatment in a murine model of invasive pulmonary aspergillosis (16). 401 
Moreover, administration of either of the two zinc-chelating agents phenanthroline or TPEN has 402 
been shown to lead to significant improvements in survival with concomitant reduction in fungal 403 
burden in immunosuppressed mice intranasally infected with A. fumigatus. Finally, it was shown 404 
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that TPEN given in combination with caspofungin significantly increased survival times in murine 405 
models of invasive aspergillosis compared to either drug alone (17).  406 
There is an unmet need for novel antifungal agents with broad-spectrum antifungal activity and low 407 
potential for resistance development for the treatment of invasive fungal infections. With potent 408 
antifungal activity both in vitro and in vivo, the ZACs fulfil these criteria and their advancement in a 409 
drug development program is therefore warranted. Interestingly, the ZACs and EDTA did not 410 
inhibit mammalian cell proliferation considerably within the first 24 h of exposure (EC50 > 28 411 
µg/mL) in contrast to TPEN (EC50 = 1.6 µg/mL), and even after 72 h of ZAC exposure we observed 412 
a >12-fold selectivity index in growth inhibition between C. albicans and HepG2 cells, but the 413 
index between A. fumigatus and HepG2 cells was limited. However, it should be taken into account 414 
that metal ions are crucial in every cellular system, including the host. Therefore, any intervention 415 
aiming to treat an infection through ion sequestration must deal with the delicate balance between 416 
positive and negative effects both in the pathogen and the host. The therapeutic safety window as 417 
well as the question about whether the ZACs can induce zinc deficiency in the host still need to be 418 
addressed. In summary, interfering with fungal zinc-dependent processes represents a promising 419 
new approach to antifungal therapy and this series of zinc attenuating compounds represents a 420 
potentially new class of antifungal agents.  421 
 422 
Materials and methods 423 
Synthesis of ZAC307, ZAC989, and ZAC623 424 
ZAC307: (2-[6-(dimethylamino)pyrimidin-4-yl]-5-phenyl-pyrazol-3-ol): a: i) N-Methylmethan-425 
amine, TEA, 2-propanol, 0 °C, 2h, evaporate, ii) Hydrazine hydrate, reflux, 2h, column 426 
chromatography, Yield 65%; b, Ethyl 3-oxo-3-phenyl-propanoate2-propanol, reflux, 1h, yield: 427 
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69%, 1H NMR (400 MHz; DMSO-d6, d): 13.2 (1H, bs), 8.49 (1H, d), 7.89 (2H, bd), 7.43 (3H, m), 428 
6.92 (1H, bs), 6.13 (H, s) and 3.17 (6H, s).  429 
ZAC989: (3-[(3S)-1-[6-(5-hydroxy-3-methyl-pyrazol-1-yl)pyrimidin-4-yl]pyrrolidin-3-yl]oxy-430 
pyridine-4-carbonitrile): a, NaH, abs. tert-butyl (3S)-3-hydroxypyrrolidine-1-carboxylate, THF, 0 431 
°C, 3h, NH4Cl, 82%; b, Diethylether, conc. HCl, 0 °C , quant.; c, Load onto SCX in methanol, elute 432 
with 1M NH3 in MeOH, 95%; d, (2-(6-chloropyrimidin-4-yl)-5-methyl-pyrazol-3-ol): (6-433 
chloropyrimidin-4-yl)hydrazine  and methyl 3-oxobutanoate 2-propanol, reflux 90 min, 14%; e, 2-434 
(6-chloropyrimidin-4-yl)-5-methyl-pyrazol-3-ol and product from c, NMP, DIPEA, 30 min at 100 435 
°C, 89%, 1H NMR (400 MHz; DMSO-d6, ): 8.84 (s, 1H), 8.46 (d, 1H), 8.42(d, 1H), 7.77 (dd, 1H), 436 
7.08 (bs, 1H), 5.59 (bs, 1H), 5.24 (bs, 1H), 3.95 (dd, 1H), 3.81 (bs, 2H), 3.68 (dq, 1H), 2.43-2.50 437 
(m, 1H), 2.35-2.40 (m, 1H), 2.19 (s, 3H). 438 
ZAC623: (3-[(3S)-1-[6-(5-amino-3-methyl-pyrazol-1-yl)pyrimidin-4-yl]pyrrolidin-3-yl]oxypyri-439 
dine-4-carbonitrile): a, tert-Butyl-N-aminocarbamate, DIPEA, THF, rt → reflux, 98%; b, 440 
Pyrrolidine from ZAC989-c, DIPEA, NMP, 120 C , 1h, 71%; c, i) TFA, DCM, rt, 30 min, ii) Load 441 
onto SCX in methanol, elute with 0.5M NH3 in MeOH, quant.; d, Z-3-Amino-but-2-enenitrile, 442 
AcOH, EtOH, 80 °C 4h, 85%. 1H NMR (500 MHz; DMSO-d6, ): 8.80 (s, 1H), 8.36 (d, 1H), 443 
8.30(d, 1H), 7.78 (dd, 1H), 6.84 (s, 1H), 6.65 (bs, 1H), 5.54 (bs, 1H), 5.21 (s, 1H), 3.81 (bs, 2H), 444 
3.61 (bs, 2H), 2.25-2.46 (bs, 2H), 2.07 (s, 3H). 445 
 446 
Fungal isolates and growth conditions 447 
Fungal isolates used in this study were purchased from either ATCC, DSMZ (Germany) or the 448 
Danish National Serum Institute (SSI), with the exception of C. glabrata strain Cg003, which was a 449 
kind gift from Julius Subik, Comenius University in Bratislava, Slovak Republic. C. glabrata 450 
Cg003 is clinical isolate 3 previously used by Berila and Subik (2010) and was characterized to be 451 
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resistant to fluconazole and itraconazole via overexpression of the multidrug resistance efflux 452 
pumps Cdr1p and Cdr2p (34). Aspergillus terreus isolate At070 was a kind gift from Herning 453 
Hospital, Denmark. The Aspergillus fumigatus strains AF14, AF54, AF48, AF721 and AF731 have 454 
previously been described previously (3, 24, 27).  455 
Candida albicans (SC5314), C. glabrata (ATCC-90030), C. glabrata (Cg003), C. krusei (ATCC-456 
6258), C. parapsilosis (ATCC-22019) and C. tropicalis (Ct016) were grown in Sabouraud broth (40 457 
g/L d-glucose, 10 g/L peptone, pH 5.6) or YPD (10 g/L yeast extract, 20 g/L Bacto-peptone, 20 g/L 458 
glucose) liquid media to mid-log phase, aliquoted into a final concentration of 20% 459 
(v/v) glycerol and maintained as frozen stocks at –80 °C. Freeze stocks of the mold isolates (A. 460 
fumigatus (ATCC-13073), A. flavus (ATCC-15547), A. terreus (At070), Rhizopus oryzae (ATCC-461 
34965), R. microsporus (ATCC-66276) and Mucor indicus (ATCC-MYA-4678)) were prepared by 462 
harvesting spores from 7-day old potato glucose agar plates in PBS containing 0.1% Tween-463 
80, and aliquoting these spores in the presence of glycerol at a final concentration of 20% (v/v). 464 
SD media without zinc (SDwoz: 1.71 g/L YNB-ZnSO4 (1541, Sunrise Science), 2% glucose, 5 g/L 465 
ammonium sulphate) was prepared in a glass beaker washed with 0.37% HCl and rinsed with water. 466 
The pH was adjusted to 7.0 with NaOH and the media was sterile by filtration. 467 
 468 
Dissociation constant determination 469 
The dissociation constant (Kd) of zinc to zinc-attenuating compounds was determined at room 470 
temperature using FluoZin-3 (F24194, ThermoFisher Scientific), which has a Kd, Fluozin-3:Zn
2+
 = 471 
15 nM (35). Testing buffer consisted of PBS pH 7.4 with 200 nM ZnCl2 and 500 nM FluoZin-3. In 472 
a microtiter plate, 98 µL testing buffer was mixed with 2 µL compound at a range of concentrations 473 
to determine the IC50. Testing plates were incubated for 2 min before reading at Ex = 485 and Em = 474 
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516 with a Fluoroskan Ascent Microplate Fluorometer, ThermoScientific. The Kds were calculated 475 
using the equation: Kd (compound:Zn
2+
) = IC50 / (1 + [Fluozin-3] / Kd,Fluozin-3:Zn
2+
) (36). 476 
 477 
Potentiometric titration 478 
Potentiometric measurements were carried out in DMSO/water (70:30 v/v) at 25 °C as described 479 
previously (22). Titrations were performed with a pH meter (Denver Instrument) utilizing a glass 480 
electrode with AgCl reference filled with 3.0 M KCl. The electrode was equilibrated in 481 
DMSO/water (70:30 v/v) for at least 1 h before use. All experiments were performed at constant 482 
ionic strength (0.1 M NaClO4).  Three millilitres of a solution containing 1 mM compound was 483 
titrated with 0.3 M NaOH by manual additions in 1-5 µL increments under magnetic stirring. The 484 
metal-ligand binding constants were obtained from titrations of the metal complex solutions 485 
prepared in a 1:2 metal-to-ligand ratio. The titration data were refined by the nonlinear least squares 486 
refinement program Hyperquad2013 (37) to determine the deprotonation and stability constants. 487 
 488 
Antifungal susceptibility testing 489 
Antifungal susceptibility testing was carried out as described previously (38, 39) with a few 490 
modifications. Briefly, for each yeast or mold growth inhibition assay, frozen stocks of yeast cells 491 
or spores were diluted to a final concentration of 0.5-2.5  10
5 
CFU/ml in sterile water. ZAC989, 492 
ZAC307 and ZAC623 were dissolved in DMSO to 10 mM stocks from which half-log serial 493 
dilutions were prepared from this. Growth assays were subsequently performed by pipetting 3 µL 494 
compound dissolved in DMSO (giving a final concentration of 1.5% DMSO), 100 µL cell/spore 495 
suspension and 97 µL 2 RPMI-media (20.8 g/L RPMI-1640 media, 69.06 g/L MOPS, 36 g/L 496 
glucose) into a microtiter plate that was incubating for 24 h (yeasts) or 48-72 h (molds) at 34 ºC. 497 
Fungal growth was determined spectrophotometrically by optical density reading of each well at a 498 
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wavelength of 492 nm on a Victor X5 (Perkin-Elmer) plate reader. The minimum inhibitory 499 
concentration (MIC) was defined as the lowest compound concentration that resulted in at least 500 
50% growth inhibition for yeast, which corresponded to a prominent decrease in visible growth. For 501 
the molds the MIC was defined as the lowest concentration of the compound that resulted in no 502 
visible growth. Standard errors between repeated experiments were generally below 5%. The 503 
growth effect of exogenous addition of various divalent metals was evaluated by performing the 504 
antifungal susceptibility assay in the presence of 5 µM of ZAC989 or ZAC307 and with increasing 505 
concentrations (0.003 - 50 µM) of ZnSO4, CuSO4, (NH4)2Fe(SO4)2, MgCl2, and CaCl2. The MFC 506 
was the minimum concentration that resulted in no colony forming units and was determined after 507 
MIC determination by plating 5 µL of the mixture from wells with no visible growth onto YPD agar 508 
plates followed by 24 h incubation at 30 °C. 509 
Growth capacity experiments with the A. fumigatus strains AF14, AF54, AF48, AF732 and AF731 510 
were performed in 24-well flat-bottomed tissue culture plates (35-3047, Falcon). A stock solution of 511 
10 mM TPEN (P4413, Sigma) was prepared in pure ethanol. For these experiments, 5 mM stock 512 
solutions of ZAC307 and ZAC989 were prepared by dissolving each compound in 80% (v/v) 513 
ethanol. A 0.5 M stock solution of Na2EDTA-2H2O (1.08421.1000, Merck) was prepared in sterile 514 
water. A 1 stock solution (10.4 g/L) of the RPMI-1641 medium (R8755, Sigma) supplemented 515 
with 10 μM FeSO4-7H2O, 1 μM CuSO4-5 H2O and 1 μM MnCl2-H2O (sRPMI) was prepared under 516 
aseptic conditions and used as standard culture medium. In each well, 1 mL of culture medium 517 
containing sRPMI medium, Tween-20, ethanol (or the specified compound dissolved in 80% 518 
ethanol) and 10
5
 conidia was dispensed, to achieve a final concentration of 0.7, 0.05% (v/v), 1.2% 519 
(v/v) and 10
5
 conidia/mL, respectively. Plates were incubated for 44 h at 37 ºC in a humid 520 
atmosphere. To quantitate mycelial growth, each plate was scanned in the Agfa SnapScan 1236s 521 
scanner, and the intensity of the wells was quantified using the open source image processing 522 
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program Image J2. The data were represented and analyzed with the Prism Software 7.0. 523 
 524 
Time-kill assay 525 
C. albicans SC5314 cells (10
5
 CFU/mL) were incubated in 10 mL RPMI media at 30°C with gentle 526 
agitation (150 rpm) in the presence of EDTA (15 µM), TPEN (10 µM), ZAC989 (10 µM) or AMB 527 
(0.5 µM). At the indicated time points (0, 3, 5.5 and 24 h), a 100-μL aliquot was removed for each 528 
test condition, serially diluted (10-fold) in saline (0.9% NaCl), and 30 μL of each dilution was 529 
plated on YPD agar plates. The colony count on each YPD plate was determined after incubation at 530 
30 °C for 48 h (40). C. albicans cells treated with DMSO (1%, v/v) served as a control.  531 
 532 
Resistance study 533 
The propensity for resistance development was investigated as also described previously (41), but 534 
with the following modifications. C. albicans was repeatedly exposed to either ZAC989 or ZAC307 535 
in 1 mL cultures in SDwoz media with a starting inoculum of OD600=0.007. A compound 536 
concentration that resulted in ~90% growth inhibition was selected for these experiments; (3.6 537 
µg/mL for ZAC989, 2.8 µg/mL and 5.6 µg/mL for ZAC307, 0.5 µg/mL and 1.0 µg/mL for 538 
fluconazole). Over a 36-day period, culture aliquots of 100 μL were periodically (every 1-2 days) 539 
transferred (passaged) to new culture tubes with 900 μL fresh media and fresh compound. The cells 540 
were incubated at 30 °C, with gentle agitation (150 rpm), and the OD600 of cultures was monitored 541 
throughout the entire period to ensure that the number of cells exposed to compounds was 542 
comparable across treatments for each passage. Cells were passaged a total of 22 times, and cultures 543 
were periodically tested for antifungal susceptibility following the protocol for antifungal 544 
susceptibility testing, as described above. 545 
 546 
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Zinbo-5 assay 547 
C. albicans BWP17 was grown overnight in YPD media at 30 °C and 150 rpm. The cells were 548 
pelleted, washed in PBS buffer (D8537, Sigma) 3 times and re-suspended to an OD600 of 2.0. Two 549 
microliters of compound in DMSO was mixed with 100 µL cell suspension and incubated statically 550 
for 1, 8 or 24 h at 30 °C in a 96-well black plate. Thirty minutes before the end of the incubation 551 
period, 100 µL of 10 µM zinbo-5 (sc-222425, Santa Cruz Biotechnology) in PBS buffer was added. 552 
The affinity constant of this probe for zinc is 2.2 nM (23). The plate was then read on a plate reader 553 
(FLUOstar Optima, BMG Lab technologies) with excitation at 355 nm and emission at 485 nm. 554 
Decrease in zinbo-5 fluorescence was calculated relative to the untreated DMSO-control.  555 
 556 
RNA isolation from Aspergillus fumigatus  557 
1.5  10
6
 conidia of the wild-type strain (AF14) were inoculated into 20 mL of 0.7 sRPMI, 0.05% 558 
Tween-20 and 1.2 % ethanol dispensed into 100-mL culture flasks pre-treated by a over night wash 559 
in 2 mM EDTA pH 8.0 to minimize the presence of metal traces followed by an thoroughly 560 
washing with ultrapure Milli-Q water. Then flasks were subsequently sterilized in an oven at 180 561 
ºC. The cultures were incubated for 20 h at 37 ºC and 200 rpm before the following was added: (1) 562 
pure ethanol to a final concentration of 1.2 % (v/v) (as a reference for the transcription profiles of 563 
all genes under zinc-limiting conditions); (2) 1.2 % ethanol plus a solution of ZnSO4 to a final 564 
concentration 20 μM zinc (as a reference for the transcription profiles of all genes under zinc-565 
replete conditions following the zinc-shift); (3) 1.2 % ethanol plus a solution of EDTA to a final 566 
concentration of 500 μM; (4) 1.2 % ethanol plus a solution of TPEN to a final concentration of 10.6 567 
μg/mL, and (5) a 5 mM solution of each test compound (ZAC307 or ZAC989) dissolved in 80 % 568 
ethanol to a final concentration of 75 μM and 1.2 % ethanol, (which corresponds to 21 µg/mL and 569 
27 µg/mL, respectively). After compound addition, cultures were incubated for 2 h at 37 ºC and 200 570 
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rpm and mycelia were harvested by filtration through filter paper, washed twice with sterile water 571 
and snap-frozen in liquid nitrogen. After grinding the mycelia in the presence of liquid nitrogen, 572 
total RNA was extracted using the RNeasy Plant Mini Kit (74904, QIAGEN) according to the 573 
manufacturer’s instructions. RNA was eluted in 50 μL of RNase-free water. RNA integrity was 574 
verified on 0.8 % agarose gels stained with ethidium bromide. RNA was stored at –80  ºC until use. 575 
 576 
RT-qPCR 577 
Total RNA concentration and quality was determined by UV spectrometry (Nanodrop ND1000 578 
spectrophotometer, Thermo Fisher Scientific) and all samples were brought to a final concentration 579 
of 150 ng/μL. Total RNA 1.5 μg was treated with RQ1 DNase I (M610, Promega) and subsequently 580 
assessed by conventional PCR for the complete absence of gDNA. Subsequently, 1 μg of DNase-581 
treated RNA was reversed transcribed using the SuperScript II Reverse Transcriptase (18064-014, 582 
Invitrogen, Thermo Fisher Scientific) using random hexamers (11034731001, Roche Diagnostics) 583 
as primers. Prior to qPCR reactions, cDNA samples were diluted 1:3 in water, except for reactions 584 
against the 18S rRNA that were diluted 1:1200 in water. qPCR reactions were performed on a 585 
BioRad CFX96 instrument. A typical qPCR reaction mixture (10 μL) contained 13.5 ng cDNA (32 586 
pg when the qPCR was for 18S rRNA), a specific pair of primers (150 nM final concentration), and 587 
the SYBR Premix ExTaq (RR420A, Takara). Primers used for qPCR are listed in Table 3. For all 588 
qPCR reactions, 40 cycles were performed using the following cycling conditions: denaturation at 589 
95 ºC for 10 seconds, annealing at 59 ºC for 20 seconds and extension at 72 ºC for 20 seconds. The 590 
relative expression ratio (rER) was calculated using the 2
–ΔΔCt
 method (42) using the expression 591 
level of the 18S rRNA as an internal reference. 592 
 593 
Human hepatocyte (HepG2) proliferation assay 594 
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In each well of a 96-well tissue culture plate (GR-655180, Grenier), 10,000 human hepatocyte 595 
(HepG2) cells (85011430, Sigma) were plated in 200 µL growth media (EMEM (M2279, Sigma), 596 
supplemented with 2 mM L-Glutamine (03-020-1B, Biological Industries), 1 % non-essential amino 597 
acids (XC-E1154/100, Biosera), and 10 % fetal bovine serum (BI-04-007-1A, Biological 598 
Industries)), and plates were incubated overnight at 37 °C and 5 % CO2. The following day, fresh 599 
growth media plus 2 µL compound in DMSO was added. The plate was incubated for a further 24 h 600 
or 72 h at 37 °C and 5 % CO2. The media was then replaced with 100 µL freshly prepared XTT 601 
sodium salt solution (0.5 mg/mL XTT; X4251, Sigma) in RPMI-1640 (R7509, Sigma-Aldrich) with 602 
3.83 µg/mL phenazine methosulfate (P9625, Sigma-Aldrich) and incubated 2 - 3 h at 37 °C and 5 % 603 
CO2 (43). The color reaction was measured on Victor X5 plate reader (Perkin-Elmer) at OD450 and 604 
the half maximal effective concentration (EC50) was calculated. Tamoxifen (85256, Sigma) was 605 
used as a positive control compound. 606 
 607 
In vivo fungal kidney burden candidiasis model 608 
A murine model of systemic candidiasis was established according to a previously described 609 
method (44). BALB/c mice were infected with a 0.1 mL inoculum (1-5  10
5
 CFU) of Candida 610 
albicans SC5314 cells by intravenous route on day 0. Compounds were tested at doses of 60 mg/kg. 611 
Administration of compound was initiated 24 h prior (day -1) to infection (day 0) by intraperitoneal 612 
route, dosing twice a day for 4 days (day -1 to day 2). ZAC307 was also evaluated with 613 
administration of the compounds given after the infection at day 0 (no pre-treatment) and with 614 
following dosing twice a day for 3 days (day 0 to 2). Fluconazole was used as a comparator drug. 615 
Six mice were used for each group and the untreated control group was exposed to the vehicle 616 
alone. ZAC989 and ZAC307 were formulated by taking 60 mg of compound and adding this to 2 617 
mL and 4 mL of 0.1 N NaOH, respectively. After mixing and sonicating the resulting solutions, 4 618 
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mL of purified water was added. The pH was adjusted to pH 9.0 with 0.1N HCl solution followed 619 
by the addition of 90 mg of NaCl. The solutions were then diluted to 10 mL and filtered through 620 
0.22 µm PVDF filter. Sample collection and processing was performed as follows: 12 h post last 621 
dose, all treated and untreated animals were sacrificed by cervical dislocation and kidneys were 622 
collected in 3 mL of sterile normal saline. The samples were homogenized, serially diluted and 623 
plated on SDA. SDA plates were incubated for 24 - 48 h at 35 °C, and CFUs were enumerated and 624 
reported as log CFU/kidney. Endpoint: Mean log CFU of fungi in kidneys of treated animals 625 
compared to that of untreated animals. The study was conducted in conformance with an 626 
application submitted to CPCSEA, New Delhi (Committee for the Purpose of Control and 627 
Supervision of Experiments on Animals) after approval from the Institutional Animal Ethics 628 
Committee (IAEC). 629 
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Figure 1. A) Structures of the compounds ZAC307, ZAC989, ZAC623, TPEN and EDTA. B) 775 
Abbreviated synthetic pathway for ZAC307: 
a
, i) N-Methylmethanamine, TEA, 2-propanol, 0 C, 776 
2h, evaporated, ii) Hydrazine hydrate, reflux (block temp 120 C), 2h, 65%; 
b
, 2-propanol, reflux, 777 
1h, 69%. C) Abbreviated synthetic pathway for ZAC989: 
a
, NaH, abs. THF, 0 C, 3h, NH4Cl, 82%; 778 
b
, Diethylether, 0 C , conc. HCl, quant. ; 
c
, Load onto SCX in methanol, elute with 1M NH3 in 779 
MeOH, 95%; 
d
, 2-propanol, reflux 90 min, 14%; 
e
, NMP, DIPEA, 30 min at 100 C, 89%. D) 780 
Abbreviated synthetic pathway for ZAC623: 
a
, tert-Butyl-N-aminocarbamate, DIPEA, THF, rt → 781 
reflux, 98%; 
b
, 3-[(3S)-pyrollidin—3-yl]oxypyridine-4-carbonitrile (see B) reac. c), DIPEA, NMP, 782 
120 C , 1h, 71%. ; 
c
, i) TFA, DCM, rt, 30 min, ii) Load onto SCX in methanol, elute with 0.5M 783 
NH3 in MeOH, quant. ; 
d
, Z-3-amino-but-2-enenitrile, AcOH, EtOH, 80 C 4h, 85%. 784 
 785 
Figure 2. Potentiometric titration results for ZAC307 and ZAC989. A) Potentiometric equilibrium 786 
curves of ZAC307 in the absence or presence of 0.5 mole equivalent of Zn(NO3)2, CaCl2 or MgCl2 787 
in DMSO/water (70:30 v/v). B) Potentiometric equilibrium curves of ZAC989 in the absence or 788 
presence of 0.5 mole equivalent of Zn(CF3SO3)2, CuSO4, CaCl2 or MgCl2 in DMSO/water (70:30 789 
v/v). C, D and E) Species distribution diagram as a function of pH for a system containing C) 0.5 790 
mM Zn(II) and 1 mM ZAC307, D) 0.5 mM Zn(II) and 1 mM ZAC989 and E) 0.5 mM Cu(II) and 1 791 
mM ZAC989. 792 
 793 
Figure 3. A) Candida albicans growth inhibition by ZAC989 and ZAC307, but not by the close 794 
analogous compound ZAC623. B) Candida albicans growth inhibition by EDTA and TPEN. C+D) 795 
Abrogation of the antifungal effect of ZAC989 and ZAC307 in Candida albicans cells was 796 
























 is required to abrogate the antifungal effects of 1.8 µg/mL ZAC989 or 1.4 µg/mL 798 
ZAC307. C. albicans growth (expressed as %) in A-D was normalized to C. albicans growth in 799 
RPMI containing 1.5 % DMSO. Graphs represent mean ± SEM for 2-3 independent experiments.  800 
 801 
Figure 4. A) Time-kill experiments with C. albicans revealed that ZACs exhibit fungistatic activity. 802 
The following final concentrations of compound were applied; 0.5 µg/mL amphotericin B (AMB), 803 
3.6 µg/mL ZAC989; 4.4 µg/mL EDTA; 4.2 µg/mL TPEN. Data shows the mean ± SEM for two 804 
biological replicates.  B and C) C. albicans cells exposed to ZAC989 and ZAC307 for 5 days 805 
resume normal growth (B), while cells exposed to TPEN for 5 days show poor recovery (C). C. 806 
albicans cells exposed to EDTA resumed visible growth after 48 h of compound incubation 807 
(concentration range 0.22 µg/mL to 22 µg/mL) and were therefore not evaluated for MFC. D) 808 
Decrease in intracellular zinc as evidenced by a decrease in zinbo-5 fluorescence signal suggests 809 
that ZAC989 and ZAC307 act intracellularly in C. albicans. The following final concentrations of 810 
compound was applied: 9 µg/mL ZAC989, 7 µg/mL ZAC307, 15 µg/mL EDTA, 1.3 µg/mL TPEN. 811 
Data shows the mean ± SEM for two biological replicates. E) Resistance induction study; no change 812 
in the MIC for the ZACs after repeated ZAC exposure, while a significant increase in the MIC was 813 
observed for C. albicans after 22 passages with repeated exposure to fluconazole (FLC) (1.0 814 
µg/mL). 815 
 816 
Figure 5. Effect of ZAC307 and ZAC989 on the growth capacity of several A. fumigatus strains. 817 
(A) The wild-type AF14 strain was cultured in 24-well culture plates inoculated with 10
5
 conidia 818 
per well in a total volume of culture media of 1 mL. Not inoculated (Ni) culture media were used as 819 
background reference. Media were not supplemented with zinc or were supplemented with 2, 5 or 820 
50 μM ZnSO4 in the absence (–) or the presence (+) of ZAC307 (Z7) or ZAC989 (Z9), as indicated. 821 
 on M








Plates were incubated a 37 ºC in a humid atmosphere for 44 h, scanned, quantified and the growth 822 
was represented graphically. (B) Effect of ZACs on the growth capacity of the ∆zrfA∆zrfB mutant 823 
strain (AF48). (C) Effect of ZACs on the growth capacity of the ∆zrfA∆zrfB∆zrfC mutant strain 824 
(AF721). (D) Effect of ZACs on the growth capacity of the ∆zrfA∆zrfB∆zrfC[zrfC] mutant strain 825 
(AF731). (E) Effect of ZACs on the growth capacity of the ∆zrfC mutant strain (AF54). The AF48, 826 
AF721, AF731 and AF54 strains were all cultured and incubated in 24-well culture plates and their 827 
growth were quantified as described for the wild-type strain. In all cases the relative arbitrary units 828 
obtained after quantification of the plates were normalized by taking the average of the background 829 
values of not inoculated cultures as a growth capacity of 0 % and the growth reached by the wild-830 
type strain in media supplemented with 50 μM zinc in the absence of ZACs as a growth capacity of 831 
100%. In all graphs, the data represent the average and standard deviation of two independent 832 
experiments in which all strains had been cultivated in duplicate. 833 
 834 
Figure 6. Effect of the ZACs, the extracellular chelator EDTA and the intracellular chelator TPEN 835 
on the transcription of ZafA target genes under zinc-limiting conditions. The wild-type strain pre-836 
cultured in the sRPMI zinc-limiting medium for 20 h at 37 ºC with shaking at 200 rpm was 837 
untreated (–Zn) or treated with 20 μM zinc (+Zn), 21 μg/mL ZAC307 (+ZAC307), 27 μg/mL 838 
ZAC989 (+ZAC989), 146 μg/mL EDTA (+EDTA) and 10.6 μg/mL TPEN (+TPEN). The 839 
expression level of the indicated genes was analyzed by RT-qPCR using 18rRNA as an internal 840 
reference. The changes in the relative expression ratios (rER) were measured after 2 h of incubation 841 
following the treatment with the different compounds and compared to the expression levels 842 
observed under zinc-limiting conditions (–Zn). The bar diagram depicts the average and standard 843 
deviation of the results obtained in two independent experiments. 844 
 845 
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Figure 7. In vivo efficacy data for ZAC989 and ZAC307 in a 3-day candidiasis kidney burden 846 
model. Dosing with and without pre-treatment (day -1) yields the same CFU reduction for ZAC307. 847 
# Indicates no pre-treatment in this arm. * p <0.05 compared to infected untreated control group, 848 
one-way ANOVA. 849 
 850 
 851 
Table 1: Dissociation constant (KD) determination between chelating compounds and zinc. KD 852 
determination for the compound-Zn
2+
 complex was performed with a fluorescence-based 853 
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Table 2. Determination of the minimum inhibitory concentration (MIC) of several different 862 
Candida species.  863 
 Fungal growth inhibition of Candida spp. 





















ZAC989 0.6 0.8 0.9 0.6 0.9 0.8 
ZAC307 0.4 0.4 0.2 0.2 0.4 0.4 
ZAC623 >54 >54 ND ND ND >54 
a
 This Candida glabrata strain has mutations resulting in increased efflux pump activity as 864 
compared to wild type isolates (34). ND: Not determined. 865 
 866 
Table 3. Minimum inhibitory concentration (MIC) determination of several different Aspergillus 867 
and mucorales species. 868 
 Fungal growth inhibition of mold isolates 


























ZAC989 5.4 5.1 1.6 1.7 0.5 1.1 
ZAC307 4.0 1.3 1.3 1.3 0.4 1.3 
 on M








Table 4. Selected genes for quantifying their relative expression level by RT-qPCR 869 
Regulation by 
ZafA 
Gene Code Function 
Regulated 
zafA AFUA_1G10080 
Major transcriptional regulator of zinc 
homeostasis 
zrfB AFUA_2G03860 
Zinc transporter of the ZIP family putatively 
located in the cytoplasmic membrane 
zrfC AFUA_4G09560 
Zinc transporter of the ZIP family putatively 
located in the cytoplasmic membrane 
zrfF AFUA_2G08740 
Zinc transporter of the ZIP family putatively 
located in vacuolar membrane 
zrcA AFUA_7G06570 
Zinc transporter of the CDF family putatively 
located in vacuolar membrane 
mchC AFUA_8G02620 Putative zinc-metallochaperone 
sarA AFUA_7G06810 Putative L-amino acid oxidase 
Not regulated actA AFUA_6G04740 Actin 
tubB1 AFUA_1G10910 -tubuline subunit 1 
gdpA AFUA_5G01970 Glyceraldehyde-3-phosphate dehydrogenase 
pmaA AFUA_3G07640 Plasma membrane H
+
-ATPase 
mchA AFUA_2G11720 Putative metallochaperone 













Table 5. Primers used to quantify mRNA by RT-qPCR. 873 
Oligonucleotide Sequence (5´ → 3´) 
18SRNA-D  TGTTAAACCCTGTCGTGCTG 
18SRNA-R  GTACAAAGGGCAGGGACGTA 
ZAFA- D1 GGCAAGTCATTTACCGACAGC 
ZAFA-R1  TCGATGACTTGACATGTTGGACG 
ZRFB-D  ACCGGCAGAAGAAGCATTGA 
ZRFB-R  ACCGCATCACCATCAACTCA 
ZRFC-D  CAAACTCTCGGTGCTCGTCA 
ZRFC-R  GAAGACAATCACCACCAGCA 
qZRFF2-D  CGTATTCCCTCTCATGTCGTCG 
qZRFF2-R  AGAGCCATTTGCCTGGTTCG 
SARA-D  GCATATCATGTCACCGAGCACA 
SARA-R  AGCCCCAACTCCAACAACAA 
qMCHC-D  CATGCTAACGATGGGATGCG 
qMCHC-R  CTTCGGTCTCCCAATGGTGG 
qZRCA-D  TGCAGAGTGTTCCTCTCGGAGTCG 
qZRCA-R  TCGCCAGATATGCAGTTCATGGACG 
qACT3-D  CCACGTCACCACTTTCAACTCCATC 
qACT3-R  TCCTTCTGCATACGGTCGGAGATAC 
qGDPA2-D  CTCACTTGAAGGGTGGTGCC 
qGDPA2-R  GATGTCGGAGGTGTAGGTGG 
qPMA12-D  AGATCGCTACTCCTGAGCACG 
qPMA12-R  CTTCTGCTCGGCAAGGTAAGC 
BTUB-D  AACAACATCCAGACCGCTCT 
BTUB-R  TGATCACCGACACGCTTGAA 
qMCHA-D  GAAACCGCAACGAGCCATAC 
qMCHA-R  ACGAGATCCGCCTTGTTCAG 
qMCHB-D  TGATCTTGAGGTGCAGACGC 
qMCHB-R  TGATGGTCATCCGTCAACCG 
  874 
 on M








Table 6. In vitro cell proliferation assay in HepG2. 875 






ZAC989 >36 6.9 ±0.7 
ZAC307 >28 13.2 ±0.8 
EDTA >29 >29 
TPEN 1.6 ±0.2 1.4 ±0.8 
 876 
Table 7. Fungal kidney burden candidiasis in vivo model 877 






















NA 2.78* 1.71* 1.06* 1.03* 
*p<0.05 compared to infected vehicle control group, one-way ANOVA 878 
NA: not applicable 879 
 880 
 on M



















































































































































































































































































































EDTA     (4.4 µg/mL) 
AMB   (0.5 µg/mL) ZAC989 (3.6 µg/mL) 







64 20 6.3 2.0 0.6
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